Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: brinzolamide

« Back to Dashboard
Brinzolamide is the generic ingredient in one branded drug marketed by Alcon Pharms Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for brinzolamide. One supplier is listed for this compound.

Summary for Generic Name: brinzolamide

Drug Master File Entries: see list8
Suppliers / Packaging: see list2
Therapeutic Class:Ophthalmic Agents

Pharmacology for Ingredient: brinzolamide

Clinical Trials for: brinzolamide

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
Status: Withdrawn Condition: Open Angle Glaucoma; Ocular Hypertension

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs
Status: Completed Condition: Primary Open Angle Glaucoma; Ocular Hypertension

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status: Completed Condition: Glaucoma; Ocular Hypertension

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
Status: Completed Condition: Open-Angle Glaucoma; Ocular Hypertension

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
Status: Completed Condition: Open-Angle Glaucoma; Ocular Hypertension

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
Status: Completed Condition: Open-Angle Glaucoma; Ocular Hypertension

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome
Status: Completed Condition: Infantile Nystagmus Syndrome

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
Status: Terminated Condition: Intraocular Pressure

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
Status: Terminated Condition: Open-Angle Glaucoma; Ocular Hypertension

24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
Status: Completed Condition: Glaucoma

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Pharms Ltd
SUSPENSION/DROPS;OPHTHALMIC020816-001Apr 1, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn